Lexaria Bioscience (LEXX) Prepaid Assets (2011 - 2026)
Lexaria Bioscience (LEXX) posted Prepaid Assets of $398765.0 for Q2 2026, down 13.09% sequentially from $458846.0 in Q1 2026, and down 51.57% YoY from $823348.0 in Q2 2025.
Lexaria Bioscience (LEXX) Prepaid Assets (2011 - 2026) Analysis & Trends
Lexaria Bioscience has reported Prepaid Assets for 16 years, with the latest figure at $398765.0 in Q2 2026.
- Quarterly Prepaid Assets fell 51.57% year-over-year to $398765.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $398765.0 (down 51.57% YoY) and the FY2025 annual result came in at $1.1 million, down 4.66% from the prior year.
- Prepaid Assets fell to $398765.0 in Q2 2026 per LEXX's latest filing, from $458846.0 in the prior quarter.
- Over five years, Prepaid Assets peaked at $1.2 million in Q3 2024 and troughed at $132311.0 in Q4 2023.
- A 5-year average of $618750.7 and a median of $561772.0 in 2022 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2023: Prepaid Assets soared 344.33% in 2022, then slumped 71.51% in 2023.
- Over 5 years, Prepaid Assets stood at $260342.0 in 2022, then plunged by 49.18% to $132311.0 in 2023, then surged by 235.66% to $444121.0 in 2024, then surged by 91.52% to $850585.0 in 2025, then plunged by 53.12% to $398765.0 in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $398765.0, $458846.0, and $850585.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 398,765.00 |
| Feb 28, 2026 | 458,846.00 |
| Nov 30, 2025 | 850,585.00 |
| Aug 31, 2025 | 1.13 Mn |
| May 31, 2025 | 823,348.00 |
| Feb 28, 2025 | 850,387.00 |
| Nov 30, 2024 | 444,121.00 |
| Aug 31, 2024 | 1.19 Mn |
| May 31, 2024 | 379,546.00 |
| Feb 29, 2024 | 266,796.00 |
| Nov 30, 2023 | 132,311.00 |
| Aug 31, 2023 | 546,783.00 |
| May 31, 2023 | 629,740.00 |
| Feb 28, 2023 | 319,591.00 |
| Nov 30, 2022 | 260,342.00 |
| Aug 31, 2022 | 576,761.00 |
| May 31, 2022 | 757,308.00 |
| Feb 28, 2022 | 1.12 Mn |
| Nov 30, 2021 | 237,223.00 |
| Aug 31, 2021 | 319,253.00 |